Atea Pharmaceuticals, Inc.

AVIR Healthcare Biotechnology

In the quarter to June 2026, EPS grew 6.82% and free cash flow grew 85.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

4.32 0.21 −4.64%
Market cap
$363.3M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
n/a
Altman Z
9.33
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
16.66 7.82 7.89 8.13
Net Debt/EBITDA
7.08 5.42 5.28 6.18
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.51) (0.35) (0.59) (0.46)
Book value per Share
3.99 3.38 2.95 2.55
Free Cash Flow
(40.37) (28.22) (46.39) (37.08)
Other line items

Show all line items

Columns are period end dates